GlassScriptPhysician profile
Callie Graves
NPI 1184189219
$4,769.23
in general payments reported to CMS, 2019-2025
25 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $266 · 2023: $709 · 2024: $725 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361 · Education: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,361.21 |
| Education | $715.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $903.89 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $648.92 | 2022-2025 | Blu-U, Odomzo, Ilumya |
| Genzyme Corporation | $487.22 | 2021-2025 | |
| Abbvie INC. | $477.58 | 2021-2025 | |
| Lilly USA, LLC | $340.76 | 2021-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $269.78 | 2023-2025 | Sotyktu |
| Ucb, INC. | $259.62 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $231.30 | 2024-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $176.22 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $166.98 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $158.65 | 2025 | |
| Organogenesis INC. | $97.05 | 2024-2025 | Affinity, Puraply Wound Matrix, Novachor |
| Amgen INC. | $84.82 | 2023-2025 | Otezla, Otezla |
| Convatec INC. | $71.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.96 | 2024-2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.83 | 2022-2025 | Jublia, Cabtreo, Siliq |
| Organon LLC | $55.86 | 2025 | Vtama |
| Kerecis Limited | $48.25 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Incyte Corporation | $45.54 | 2025 | Opzelura |
| Mallinckrodt Hospital Products INC. | $35.11 | 2024 | Acthar |
| Galderma Laboratories, L.P. | $26.21 | 2021-2025 | Nemluvio |
| Triad Life Sciences INC. | $22.47 | 2022 | |
| Pfizer INC. | $16.56 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.15 | 2024 | Ycanth |
| Smith+Nephew, INC. | $14.61 | 2025 | Pico |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.